ERBB2 and breast cancer: For HER2+ BC patients not achieving pCR, they could potentially receive T-DM1 in adjuvant therapy, with reduced free of invasive disease rate and distant recurrence rate by 11.3% and 6.7% in 3-year follow-up, respectively (57).